angelica peebles on viking. we should mention that eli l lilly, down 2%. $1117 from wolf. this is really interesting, because if it goes to a phase three on the injectable side, this could mean it's the third to market on the injectables. which would be -- >> okay, but when you say to market, the time between now and then, assuming -- >> it is the most advanced in terms of the next injectable to come. >> they're still behind. >> exactly. >> so, it could be the third to market at this point. >> i don't know -- even if -- >> even if it works, i think they get bought. >> oh. >> right. good for then. they raised $600 million, $85 a share, good for then. >> right. >> buys them all kinds of type. so, they can advance the ball. may they aren't the ones to market it. >> i see what you're saying. they have $960 million in cash right now and angelica said $300 million is the cost for phrase three. >> let's play it out. jared holz was just here. and as horrible as i am, this is one we've done a great job on, i think. when it had that huge runup, we cautioned about ge

angelica peebles is back at headquarters.ke this isn't already a somewhat crowded field. why are they doing this? >> yeah. well, they're planning to start more studies of an experimental weight loss pill later this year after encouraging results from early tests. now these next studies will focus on finding the right dose of the drug. pfizer telling me that that work should be done in the first quarter of next year. this is a pill that's taken once day. pfizer was originally testing a version of the drug danuglipron that needed to be taken twice a day. they scrapped that last year after so many people dropped out of the trial because of side effects like nausea. this reformulated version kiz to keeping pfizer in the obesity race. like you said it's crowded but they have other experimental drugs in the pipeline and this is the one that's furthest along. we should note that this work is still pretty early. pfizer needs to study the pill in much larger and longer clinical trials. evercore pointing out that pfizer at this point i

angelica peebles, it'd be up even more if not for the drag amer merck is today. >> yeah, gardasil isove. second quarter sales of $2.48 billion coming up just short of analysts's estimates. the bigger concern is china. that market representing 70% of gardasil's international sales. merck seeing a, quote, significant step down in shipments of gardasil in china. executives saying they were surprised by the sudden change and have a few ideas about what's going on. there's china's anti-bribery and anti-corruption campaign. merck's chinese distributor focused on other priority. overall decline in the hpv market. merck executives are still confident gardasil can reach $11 billion in sales by 2030. clearly, this is shaking some investors. people don't like surprises. that's especially important because gardasil is merck's second largest pharmaceutical product and key to the future beyond cancer drug keytruda, which should go off patent in 2028. >> angelica, appreciate that. bryn joining us now on microsoft. give us your feelings ahead of this critical report. >> so first of all, we know they

angelica peebles today. >>> meantime, shares of uber and lyft moving higher today. office has struck a deal with the ride-sharing companies to reign in lockouts and stop onboarding new drivers. in exchange, the city's taxi regulator has agreed to not slap new rules on the companies. uber and lyft have reportedly been locking drivers out of their apps mid-shift to avoid paying them for idle time between rides. there's that, and in addition, uber, david, announcing this partnership with byd outside of the u.s., on evs and autonomous. so they're having to deal with regulators certainly at the municipal and the national -- >> and the state level, as we know, as well. california had an important ruling last week that was favorable to them as well, in terms of how you treat drivers. the stocks didn't react too much to that at the time. back here, of course, we're keeping a close eye on microsoft shares, which are down about 1.5%, but nvidia after a bad day in the market yesterday is up dramatically. over 10%. that's a very large gain for nvidia, in part because of that hu

let's get over to angelica peebles at cnbc headquarters and she has astrazeneca's ceo. >> hey, david. first about the quarter because like sara mentioned, you had a pretty good quarter. you're raising guidance for the rest of the year, but your stock is down today. walks through the dynamics we saw in the quarter and what we should expect to see from you for the rest of the year. >> thank you. first of all, thank you for having me today and for asking a very important question. we did have a tremendous first half. 18%. we had a rate cut second quarter. every part of the company is growing strongly. oncology 22%, biopharma 22%. rare disease 15%. every geography is growing. u.s., europe. china is rebounding, growing 15%. emerging markets out of china are tremendously growing. really tremendous growth and we are very much on track with what we said was our ambition. we raised the guidance for the year. now, there's a variety of things that people have reacted to. first of all they see we continue to invest heavily in r&d. the second half of the year we will have a moderated investment an